Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

Dutasteride may cause retrograde alopecia, with users experiencing hair loss on the neck and sides. Some users report slight improvement in hair thickness on top but no overall regrowth.

The user is experiencing new hair growth after using oral dutasteride, topical minoxidil, and microneedling, but is concerned about black dots on the hairline, which might be clogged pores or dormant follicles. The user previously used a topical minoxidil/finasteride spray and had good results, despite a shedding phase after switching treatments.

The conversation is about hair loss treatments, specifically Pyrludimide (KX-826) and Breezula (clascoterone), with the user unable to tolerate finasteride and dutasteride. The user plans to use these treatments alongside minoxidil, considering the efficacy and availability of each option.

Trans woman experiences hair thinning despite low testosterone and treatments like finasteride and microneedling. Possible causes discussed include past eating disorder and current stack of medications and supplements.

A user experiencing diffuse thinning at the hairline after 12 months on finasteride is considering adding minoxidil, dutasteride, or RU58841 to their treatment. Another user suggests adding minoxidil now, holding off on dutasteride, and shares personal side effects from RU58841.

The user is considering RU58841 and has been using dutasteride since age 17. They are seeking affordable SARD options, mentioning ASC-J9, GT20029, and AH001.

The conversation discusses a hair loss treatment regimen involving high doses of dutasteride, finasteride, and minoxidil, with concerns about safety and potential side effects. Users advise against the excessive use of these medications, suggesting more moderate approaches and consulting a doctor.

Clascoterone in Winlevi, a topical AR antagonist, is being re-examined due to concerns about HPA axis suppression in adolescents, but it's unlikely to be banned for adult use in androgenetic alopecia (AGA). The European Medicines Agency recommended refusing Winlevi for acne vulgaris, but this may not affect Breezula's approval for AGA.

A 42-year-old user shared a 4-month update on their hair regrowth using a "nuclear stack" including oral and topical minoxidil, dutasteride, RU58841, micro-needling, keto shampoo, saw palmetto, biotin, multivitamins, scalp massages, and inversion table. They reported significant progress with minimal side effects and plan to continue the routine.

Low Dose Naltrexone (LDN) may reduce inflammation in alopecia conditions. It is discussed as a potential adjunct treatment with finasteride or dutasteride for androgenic alopecia.

Diffuse thinners often experience more hair regrowth with DHT blockers like finasteride, possibly due to less DHT sensitivity and the presence of miniaturized, not completely bald, follicles. However, regrowth varies widely among individuals, influenced by factors like genetics, the stage of hair loss, and treatment methods such as minoxidil, microneedling, and dermarolling.

An 18-year-old is using a high-dose hair loss treatment regimen including finasteride, minoxidil, dutasteride, and plans to add RU58841 and bimatoprost, despite warnings from others about the risks. The user is determined to reverse hair loss but acknowledges the potential dangers and does not recommend others follow their approach.

Minoxidil, PRP, low-level light therapy, stem cell therapy, mesotherapy, Acell, and microneedling are discussed as treatments for thickening fine hairs in NW5 hair loss sufferers. A hair transplant may be necessary for significant improvement.

The user plans to aggressively treat hair loss by using 1.25mg finasteride daily, 1mL minoxidil twice daily, and topical dutasteride with microneedling weekly, despite experiencing side effects from finasteride previously. They intend to switch to a maintenance routine with topical minoxidil and dutasteride after regaining hair.

The conversation discusses a hair loss treatment regimen involving dutasteride, pyrilutamide, oral minoxidil, and microneedling, with the aim of suppressing DHT and stimulating hair growth. Users debate the effectiveness and potential side effects of these treatments, noting that individual results may vary and that no treatment is foolproof.

A 42-year-old had 2,100 grafts transplanted to the frontal third of the scalp, using treatments like Dutasteride, oral Minoxidil, ketoconazole shampoo, dermarolling, and PRP. They plan to add RU58841 and have scheduled SMP to improve cosmetic results.

Clascoterone, a topical anti-androgen, is generating interest for potentially fewer systemic side effects. Users are curious about its effectiveness and details like concentration and duration of use.

Clascoterone stopped shedding for one user, but no visual regrowth was noted after 3 months. The user experienced side effects with finasteride, dutasteride, and RU58841, but not with oral minoxidil and clascoterone.

Twist-1 is being explored as a promising early-stage hair loss treatment, while Scube-3's effect on Twist-1 in breast cancer cells raises concerns about its use for hair loss. The conversation discusses the potential differences in protein effects across various cell types.

The user experienced significant hair regrowth using 5mg oral Minoxidil and 0.5mg oral Dutasteride daily, with no side effects except increased body and eyebrow hair. They are concerned about progress plateauing but have not experienced shedding.

KX-826 Phase II results show that a 0.5% concentration performs better than 1% for treating male pattern baldness. Concerns about receptor upregulation from long-term DHT antagonism were mentioned.

Scube3 trials have not started yet. Treatments discussed include Minoxidil, finasteride, and RU58841.

GT20029 showed significant hair growth and safety in phase II trials, with no adverse sexual events. Users are hopeful but concerned about future costs and systemic effects.

A 22-year-old male with hair loss is considering treatments like finasteride, minoxidil, and derma rolling after being diagnosed with MPB, vitamin D deficiency, and dandruff. He seeks advice on whether these treatments can realistically improve his hair density and achieve a healthier NW2.

Men with hair loss might have lichen planopilaris (LPP), which can mimic androgenetic alopecia, leading to misdiagnosis and ineffective treatment with finasteride or dutasteride. Proper diagnosis, including biopsies, is crucial to distinguish between androgenetic alopecia and conditions like LPP.

The user's hair appears to have improved, looking thicker and healthier, especially around the temples, after using topical minoxidil, finasteride, dutasteride, and tretinoin. Most participants agree the last picture shows significant improvement, though one disagrees.

The user has been using topical minoxidil for over a year and added kx826/pyrilutamide to improve hair growth, avoiding finasteride due to side effects like lowered libido and panic attacks. They report positive results with reduced shedding and healthier hair, particularly in areas previously unresponsive to minoxidil.

Baldness is difficult to cure because current treatments like finasteride, dutasteride, and minoxidil only prevent hair shedding, and new developments are mostly ineffective. Botox shows potential in aiding skin regeneration and hair growth, but maintenance therapy with treatments like dutasteride and minoxidil may still be necessary.

KX-826 is undergoing Phase III trials in China as a potential treatment for male pattern baldness, with some users considering it as an alternative or addition to finasteride and dutasteride. Opinions on its effectiveness vary, with some users reporting positive results and others finding it expensive and ineffective.

The user shared progress on hair regrowth using 5mg oral Minoxidil and 0.5mg oral dutasteride daily, noting no side effects except for hairier eyebrows and hands. Users suggested considering a hair transplant, adding topical treatments, and continuing the regimen for further improvement.